SIO GENE THERAPIES
DEAD

Serial Number

90340409

Owner

Sio Gene Therapies Inc.

Attorney

Allison Strickland Ricketts

Filing Date

Nov 24, 2020

Add to watchlist:

No watchlists yet
View on USPTO

SIO GENE THERAPIES Trademark

Serial Number: 90340409

SIO GENE THERAPIES is a trademark filed by Sio Gene Therapies Inc. on November 24, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Sio Gene Therapies Inc. (2 trademarks)

New York, NY 10036

Entity Type: 03

Trademark Details

Filing Date

November 24, 2020

Registration Date

Not Registered

Published for Opposition

December 28, 2021

Goods & Services

Pharmaceutical preparations for human use used for the treatment of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders, excluding non-medicated cosmetic preparations, preparations for the treatment of skin-related diseases and disorders, and anti-aging and anti-wrinkle skin care prevention preparations and treatments; biologic preparations for medical and therapeutic purposes used for the treatment of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders, excluding non-medicated cosmetic preparations, preparations for the treatment of skin-related diseases and disorders, and anti-aging and anti-wrinkle skin care prevention preparations and treatments

Providing health and medical information; providing medical and health information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions; all of the foregoing used for the treatment of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders, excluding non-medicated cosmetic preparations, preparations for the treatment of skin-related diseases and disorders, and antiaging and anti-wrinkle skin care prevention preparations and treatments

Scientific and technological services and research and design relating thereto in the field of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders; pharmaceutical, biomedical and biological therapeutic research services in the field of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders; research in the fields of pharmaceutical and biologic therapeutic preparations, clinical trials and post-market trials in the field of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders; pharmaceutical research and development in the field of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders; providing scientific research information in the fields of pharmaceuticals, biomedicine, clinical trials and post-market trials in the field of central nervous system and other neurological diseases and disorders, metabolic diseases and disorders, ocular diseases and disorders and cardiovascular diseases and disorders; all of the foregoing excluding non-medicated cosmetic preparations, preparations for the treatment of skin-related diseases and disorders, and anti-aging and anti-wrinkle skin care prevention preparations and treatments

Filing History

ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Jan 26, 2023 MAB5
ABANDONMENT - AFTER PUBLICATION
Jan 26, 2023 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Jan 25, 2023 EXAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 23, 2022 EXRA
SOU EXTENSION 1 GRANTED
Aug 19, 2022 EX1G
SOU EXTENSION 1 FILED
Aug 19, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 19, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 22, 2022 NOAM
REVIEW OF CORRESPONDENCE COMPLETE
Feb 1, 2022 CORV
POST PUBLICATION AMENDMENT - ENTERED
Feb 1, 2022 CHPB
ASSIGNED TO PETITION STAFF
Jan 31, 2022 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jan 20, 2022 EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jan 19, 2022 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 28, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 28, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 8, 2021 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Nov 23, 2021 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Nov 19, 2021 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 17, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 11, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 10, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 10, 2021 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 12, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 12, 2021 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 12, 2021 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 10, 2021 GNRN
NON-FINAL ACTION E-MAILED
May 10, 2021 GNRT
NON-FINAL ACTION WRITTEN
May 10, 2021 CNRT
ASSIGNED TO EXAMINER
May 8, 2021 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 2, 2021 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 30, 2021 NWOS
NEW APPLICATION ENTERED
Nov 27, 2020 NWAP